| Trial ID: | L4800 |
| Source ID: | NCT02222623
|
| Associated Drug: |
Glargine
|
| Title: |
The Inova Type 2 Diabetes Mellitus Study
|
| Acronym: |
InovaDM2
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes, Type 2
|
| Interventions: |
DRUG: Glargine|DRUG: NPH
|
| Outcome Measures: |
Primary: Mean daily blood glucose, 5 days | Secondary: Percent of total BG readings within target BG 70-180 mg/dL before meals., 5 days|Number (Percent) of episodes and total BG readings of hypoglycemic events (BG < 70 mg/dL), 5 days|Number (Percent) of total BG readings of severe hyperglycemia (BG > 300 mg/dL) after the first day of treatment., 5 days|Hospital mortality, 5 days | Other: Mean total daily dose of insulin, 5 days|Length of hospital stay, within first 30 days of admission
|
| Sponsor/Collaborators: |
Sponsor: Inova Health Care Services
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-04
|
| Completion Date: |
2016-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-05
|
| Locations: |
Inova Fairfax Hospital, Falls Church, Virginia, 22042, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02222623
|
